01385nas a2200181   4500000000100000008004100001260001200042653001400054653001600068653001400084653001700098653001000115653001400125100001100139245007200150520096700222022001401189       2025                            d  c10/202510aAlpha-gal10aAnaphylaxis10aAntivenom10aenvenomation10aSnake10asnakebite1 aDart R00aSnake Antivenom Reactions: A New Finding and Continued Controversy.3 a<p>The role of snake antivenom in the management of venomous snakebite has been debated for decades. In this issue of&nbsp;<em>Annals</em>, Filip et al<a aria-label="Reference 1" href="https://www.annemergmed.com/article/S0196-0644(25)01237-5/abstract#"><sup>1</sup></a>&nbsp;reveal a new finding that clarifies our understanding of acute antivenom reactions and may change our use of snake antivenoms. Before 2001, the only product available in the United States was Antivenom Crotalidae Polyvalent (Wyeth). Introduced in the 1950s, the Wyeth antivenom was effective but caused acute and delayed (serum sickness) reactions. The product occasionally triggered life-threatening anaphylaxis, which caused many clinicians to avoid its use.<a aria-label="Reference 2" href="https://www.annemergmed.com/article/S0196-0644(25)01237-5/abstract#"><sup>2</sup></a>&nbsp;It was voluntarily withdrawn by the manufacturer following the introduction of a safer product.</p>
  a1097-6760